SCHEDULE: Laurion Capital Discloses 6.06% Stake in Immunic, Inc.

Laurion Capital Management LP and associated individuals report beneficial ownership of 6.06% of Immunic, Inc.'s common stock, including shares issuable from warrants.

Summary

• Laurion Capital Management LP, along with Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, have reported beneficial ownership of 839,526 shares of Immunic, Inc. common stock.
• This holding represents 6.06% of the company's outstanding shares as of June 30, 2026.
• The reported shares include 610,326 directly held shares and 229,200 shares issuable upon the exercise of warrants.
• The filing is made under Schedule 13G, indicating the reporting persons are not attempting to influence or control the issuer.
• The reporting persons are identified as an investment adviser (Laurion Capital Management LP) and individuals associated with its general partner.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new operational or financial disclosures.

Positives

• The filing clearly states the aggregate beneficial ownership, providing transparency to the market.
• The reporting persons are classified as an investment adviser, suggesting investment activity based on analysis rather than control.
• The ownership percentage is based on a specific date (June 30, 2026), providing a clear snapshot.

Negatives

• The filing does not provide any new operational or financial performance data for Immunic, Inc.
• The disclosure of warrants indicates potential future dilution if exercised, though this is a standard financial instrument.

Risks

• Potential for future share price volatility if the reporting persons decide to increase or decrease their stake significantly.
• The exercise of warrants could lead to dilution of existing shareholders' equity if not managed appropriately by the company.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Immunic, Inc. It solely reports on the beneficial ownership of securities by Laurion Capital Management LP and associated individuals.

Management Comments

• The filing should not be construed as an admission that any of the reporting persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors crossing certain ownership thresholds. This filing indicates Laurion Capital Management LP has taken a significant, though not controlling, position in Immunic, Inc., a biopharmaceutical company.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes. Potential for future market activity by Laurion Capital Management LP could influence share price.
• Creditors: No direct impact indicated by this filing.
• Employees: No direct impact indicated by this filing.
• Suppliers: No direct impact indicated by this filing.
• Customers: No direct impact indicated by this filing.

Next Steps

• The reporting persons will continue to hold their shares of Immunic, Inc. common stock.
• Any future changes in beneficial ownership exceeding reporting thresholds will necessitate new filings.
• Immunic, Inc. will continue its operations and report its financial and operational results in subsequent filings.

Key Dates

Keywords

Immunic, Inc., Laurion Capital Management LP, Schedule 13G, Beneficial Ownership, Warrants, Investment Adviser, SEC Filing